Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma portending an aggressive clinical course; the blastoid and pleomorphic morphological variants have an even worse prognosis. In addition, patients with classic morphology and a high proliferation index (HPI), also have reduced survival. Although variants have been defined, to the authors' knowledge the ability to detect these subtypes by fine-needle aspiration biopsy (FNAB) has not been described.
INTRODUCTION
The usefulness of fine-needle aspiration biopsy (FNAB) in the evaluation of lymphoproliferative disorders has been widely discussed in the literature, with both strong opponents and advocates. In clinical practice, FNAB with rapid on-site evaluation (ROSE) is part of the accepted procedure by allowing the appropriate triage of undiagnosed lymphadenopathy and ensuring the submission of fresh tissue for flow cytometric analysis. When combined with flow cytometry, the sensitivity of FNAB ranges from 84.6% to 87% and its specificity ranges from 93% to 100% for the detection of deep-seated lymphomas. 1 When combined with core needle biopsy (CNB), the rate of achieving a lymphoma diagnosis ranges from 70% to 98%, 2 with a subtype-specific lymphoma diagnosis rate of 74%. 3 In addition to other B-cell lymphomas, the cytomorphology of mantle cell lymphoma (MCL) on FNAB has been well described; however, to the best of our knowledge, the accuracy of the identification of MCL variants by FNAB has not been evaluated to date.
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Two pathogenic pathways leading to MCL currently are recognized. The traditional pathway due to immunoglobulin heavy-chain variable-unmutated B cells involves lymph nodes and extranodal sites, may undergo morphologic transformation, and expresses SRY-related HMG box 11 . Alternatively, in the leukemic pathway, immunoglobulin heavy-chain variable-mutated B cells occupy the bone marrow, peripheral blood, or spleen and are negative for SOX-11. 4 FNAB would most likely be used in cases evolving along the traditional pathway. MCL often consists of a uniform population of small lymphocytes, but distinct variants such as the blastoid and pleomorphic subtypes are defined by distinctive cytomorphologic features. Both the blastoid and pleomorphic variants can have high Ki-67 rates, and cases of MCL with classic morphology recently also have been associated with elevated proliferation indices. 5 MCL portends an aggressive clinical course, and to the best of our knowledge is incurable, even with current therapies. Therefore, the early and accurate recognition of MCL variants is important due to their potential prognostic and therapeutic ramifications. The current study evaluated the accuracy of diagnosing MCL on lymph node FNAB specimens and subtyping variants using a multiparameter approach.
MATERIALS AND METHODS
All CNB specimens diagnosed as MCL with a concurrent FNAB obtained between January 2010 and June 2016 at The University of Texas MD Anderson Cancer Center in Houston were included in the current study, which was approved by the institutional review board with a waiver of consent. Demographic, clinical, and follow-up data were compiled using the electronic medical record. Diagnoses of FNAB were compared with the concurrent CNB specimen to determine the diagnostic and morphologic concordance. All cases fulfilled the World Health Organization diagnostic criteria for MCL. 4 FNAB and flow cytometry data subsequently were reviewed by an individual with subspecialty interest and training in hematopathology and cytopathology. The variants of MCL assessed included classic MCL ( Fig. 1 ), blastoid MCL ( Fig. 2 ), pleomorphic MCL (Fig. 3) , and high proliferation index MCL (MCL-HPI) (Fig. 4) . The blastoid subtype was defined as having cells with enlarged nuclei and fine chromatin, whereas the pleomorphic subtype was considered to be large cells with irregular nuclear contours or bizarre forms. All FNAB specimens underwent ROSE for specimen adequacy and adequacy of the rinse solutions for flow cytometric analysis or other ancillary studies as appropriate. ROSE was performed by a cytopathologist viewing both air-dried Diff-Quik-stained specimens and specimens fixed in Carnoy solution and stained using the Papanicolaou method. A portion of the aspirate was rinsed in Roswell Park Memorial Institute 1640 medium (RPMI-1640) (Roswell Park Cancer Institute, Buffalo, New York), and an automated cell counter (Coulter Electronics, Hialeah, Florida) was used to count mononuclear cells. If the initial cell counts were low (<500,000 cells), additional passes then were added to the rinse whenever feasible. If the RPMI rinse solution contained clots or particulates, a cell block preparation then was made. In selected cases, cytospin preparations (Cytospin 11; Shandon Southern Instruments, Sewickley, Pennsylvania) were prepared after Ficoll-Hypaque (Accurate Chemical and Scientific Corporation, Westbury, New York) gradient separation. Immunoperoxidase staining was performed on cell block sections or cytospin preparations in selected cases.
The Ki-67 proliferation index was determined on CNB by manually counting 1000 cells in representative areas and determining the percentage with any positive staining. In the majority of cytology cases, Ki-67 and CD3 were determined by manually counting at least 100 cells on separate mononuclear cell concentrated cytospin preparations. The Ki-67 rate was reported as the percentage of Ki-67 staining/(1-percentage of CD3 staining). On cell block sections, 100 cells (preferably in areas of tissue fragments) were counted manually and the percentage of Ki-67 staining was reported. Any nuclear staining was considered to be a positive result. MCL cases with HPI were defined as cases with classic morphology and a Ki-67 score of >40%.
The flow cytometry results were available for interpretation by both the hematopathologist and the Cancer Cytopathology January 2019 cytopathologist, and these results typically were incorporated into the FNAB and CNB report. Multiparameter flow cytometric immunophenotyping data were reviewed to assess for a traditional MCL immunophenotype, characterized by bright expression of CD19, CD5, and FMC-7 and the absence of CD10, CD23, and CD200. Immunoperoxidase stains for cyclin-D1 and SOX-11 were evaluated when available.
Statistical Analysis
Continuous variables were reported as the means and standard deviations and were compared using the Student t test for unpaired data whereas binary outcome variables were compared using the 2-proportions test and the Fisher exact test (2-tailed test). A P value ≤.05 was considered to be statistically significant.
RESULTS

Patient Demographic and Clinical Data
A total of 146 patients with 172 paired FNAB and CNB specimens were diagnosed with MCL during the specified time period. The mean age of the patients ± the standard deviation was 65.8 ± 9.8 years (range, 35-90 years) and included 117 men and 29 women (male-to-female ratio of 4:1). The majority of patients had a prior history of MCL (129 of 146 patients; 88%). Prior excisional lymph node biopsy was performed at an outside institution in 48 patients. In-house excisional biopsies were performed in 1 patient prior to and in 2 patients subsequent to the reviewed case. The classic subtype was diagnosed in 61% of patients (89 of 146 patients; 58% of biopsies [99 of 172 of biopsies]) and variant morphology was identified in 39% of patients (57 of 146 patients; 42% of biopsies [73 of 172 biopsies]). Twenty-nine patients were classified as having variant morphology at the time of diagnosis, whereas 28 patients underwent transformation during the course of follow-up. The average time to transformation was 44.2 months (range, 6.5-158.1 months). The average size of the sampled lymph nodes was found to be slightly larger in the variant groups compared with the patients with classic MCL (2.8 cm vs 2.3 cm; P = .0166).
MCL Variant Subtyping by FNAB and CNB
A diagnosis of MCL was obtained in 94% of FNAB specimens (161 of 172 pairs) with flow cytometry. An additional 7 cases were diagnosed as B-cell lymphoma, not otherwise specified, and 4 cases were nondiagnostic due to limited tissue sampling. Two patients had a history of variant morphology but concurrent FNAB and CNB both demonstrated classic morphology. No cases demonstrated small cell or marginal zone-like morphology. The distribution of diagnoses by FNAB and CNB is shown in Table 1 . FNAB detected MCL variant in 74% of cases (54 of 73 cases) but failed to detect variant morphology in 18 cases. The diagnosis of a variant MCL by FNAB was in agreement with the concurrent CNB in 45 of 73 cases (62%); however, when specifying the exact subtype, this agreement decreased to 37 of 73 cases (51%). There were 5 cases in which FNAB diagnosed variant MCL, but we were unable to corroborate these cases using the concurrent CNB or subsequent tissue sampling: 2 cases were denoted as blastoid and 3 cases as MCL-HPI. Overall, the sensitivity for FNAB to detect MCL variant morphology was found to be 74% and the specificity was 93%.
Ancillary Studies
Flow cytometry was performed in 160 of 172 FNAB specimens (93%) (data available for FMC-7 only in 82 cases and for CD200 only in 132 cases). A nontraditional immunophenotype was found in 44% of cases (29 of 66 cases) with variant morphology compared with 19% of cases with classic morphology (18 of 94 cases) (P = .0008). Unusual flow cytometric findings in cases of classic MCL included dim/partial CD5 expression (9 cases), complete loss of CD5 (3 cases), partial expression of CD23 (6 cases), and complete loss of FMC-7 (2 cases). For variant cases, nontraditional findings included dim/ Immunoperoxidase staining for cyclin D1 was positive in 35 of 37 cases using either cell block section or cytospin preparations of FNAB specimens. Stain interpretation was considered noncontributory in one case due to high background staining. Cyclin D1 was positive in all 153 cases performed on formalin-fixed paraffin-embedded (FFPE) sections of CNB specimens; 2 cases exhibited only weak or focal staining. Similarly, SOX-11 immunoperoxidase staining was positive in 16 of 18 FNAB specimens and 39 of 40 CNB specimens. The CNB case that was negative for SOX-11 was found to be positive for cyclin D1 and was found to have a typical MCL immunophenotype on flow cytometry. A Ki-67 immunoperoxidase stain was used to determine the proliferation rate and a cutoff value of >40% in malignant cells defined cases as having a high proliferation index. 6 Using this designation, 27 cases with otherwise classic morphology were considered to be variant MCL. Ki-67 was performed on FNAB specimens using either cytospin preparations or cell block sections in 85 cases and on 132 FFPE sections of CNB specimens. The comparison of Ki-67 between FNAB and CNB specimens is shown in Table 2 . Between paired stains, the average difference in the Ki-67 reported rate was 15.7% ± 14.5% with a tendency toward higher rates on FNAB. A t (11;14) immunoglobulin H (IgH)-CCND1 gene rearrangement was identified by fluorescence in situ hybridization in all 5 submitted cases (performed on 3 FNAB and 4 CNB specimens).
DISCUSSION
MCL is an aggressive small B-cell lymphoma with poor overall survival (OS). Both clinical and pathologic factors predict a more adverse prognosis. Older age and poor performance status along with elevated lactate dehydrogenase (LDH) levels and a high white blood cell count comprise the 4 independent prognostic factors defining the MCL International Prognostic Index used to stratify patients in low-risk, intermediate-risk, and high-risk groups. 7 In addition, cases with elevated LDH, peripheral leukocytosis, and a high proliferation index have an increased risk of blastoid transformation. Variant morphology either can be present at the time of diagnosis or develop over the course of the disease. In the current study population, approximately 17% of patients with MCL presented with variant morphology, a finding that was similar to that of prior studies. 8 The estimated risk of blastoid transformation has been reported to be 35% at 3 years and 42% at 5 years. 8 The current study included a high percentage of MCL variants compared with the majority of institutions because the study institution is a large referral center with clinical expertise in treating patients with leukemia and lymphoma, especially those with an advanced stage A helpful tool with which to raise suspicion of variant morphology is the detection of a nontraditional MCL immunophenotype. We found that up to 44% of variant cases had an unusual immunophenotype by flow cytometry or immunohistochemistry compared with 19% of classic MCL cases. It is interesting to note that we found cases of variant MCL were more likely to have aberrant expression of CD10 and more likely to have abnormal expression of 2 antigens. CD10 expression has been shown to correlate with MCL cases with a higher mean proliferative index.
14 In contrast, another study detected an aberrant immunophenotype in 19 of 48 classic and 2 of 4 variant MCL cases, including 3 cases of classic MCL demonstrating 2 aberrant markers. However, this study included few blastoid cases and considered cases with classic morphology with elevated Ki-67 to be classic MCL. 15 Ki-67 is known to have a prognostic impact, with higher scores found to be independently associated with shorter OS and progression-free survival, independent of the MCL International Prognostic Index. 5, 7, 16, 17 Even among variant cases, Ki-67 values have been found to be an independent prognostic factor irrespective of cytomorphology. 5 Although blastoid cases generally have high proliferation rates of at least 60% to 80%, 5,6 some cases with classic morphology also have high rates. We identified 27 cases with classic morphology and an elevated proliferation index. Ki-67 expression in the majority of our classic cases was 10% to 20%, whereas it was 65% to 90% for blastoid and pleomorphic MCL cases, similar to previously reported Ki-67 rates for classic and blastoid MCL. 5, 6, 8 A proliferation rate cutoff value of 40% was used in the current study to define cases as having a high proliferation index. A proliferation index of <40% has been proposed as being suggestive of classic morphology 6 whereas cutoff values of as low as 20% and 30% have been reported to have a meaningful impact on patient survival. 18, 19 Failure to perform Ki-67 indexing in patients with classic morphology may result in an underestimation of the clinical prognosis. It is arguable that a proliferative marker should be performed for all new diagnoses and even on subsequent cases with a prior low Ki-67 rate to detect early disease progression or an increase in Ki-67; this was illustrated by a case in which an elevated Ki-67 level identified on cytology was succeeded by transformation to variant morphology. We observed a 15.7% higher proliferation index by Ki-67 on FNAB specimens compared with CNB specimens. In the majority of cytology cases, Ki-67 immunoperoxidase staining was performed on air-dried ethanol-fixed cytospin slides prepared from ficoll-purified needle rinse concentrates. These cytospin preparations produced a monolayer of disaggregated and nonoverlapping cells in which the entire nucleus was represented. Because these were airdried ethanol-fixed slides, the nuclei were considerably larger than those noted in CNB sections. Consequently, any Ki-67 staining was readily observable. We attempted to normalize the Ki-67 rate to account for the presence of contaminating T cells from the peripheral blood (the amount of which varies significantly from FNAB specimen to FNAB specimen) and the lack of architecture by performing both Ki-67 and CD3 stains. 20 to the best of our knowledge no such recommendations exist for cytology preparations. The variable appearance of MCL cytomorphology brings a broad differential to attention. Atypical lymphoid cells combined with a clonal B-cell population by flow cytometry will exclude a reactive lymphoid process. When classic MCL is suspected, other small B-cell lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone lymphoma, and follicular lymphoma should be considered. Of these, CLL/SLL can be troublesome to differentiate from MCL because both aberrantly express CD5. Additional markers are helpful because CLL/SLL characteristically expresses CD23 and CD200 but is negative for FMC-7, whereas MCL typically is positive for FMC-7 but negative for CD23 and CD200. However, as demonstrated in the current study, there can be considerable overlap when MCL exhibits a nontraditional immunoprofile, especially for cases with variant morphology. Diffuse large B-cell lymphoma, Burkitt lymphoma, and acute lymphoblastic lymphoma come into the differential diagnosis when assessing a case of a blastoid MCL. It is important not to mistake a case of blastoid or pleomorphic MCL for diffuse large B-cell lymphoma with CD5 expression. The latter can occur in approximately 5% to 10% of cases of diffuse large B-cell lymphoma but generally arise de novo, or less commonly within the setting of prior CLL/SLL, and will lack expression of cyclin D1 and SOX-11. 4 Both B-cell and T-cell lymphomas with anaplastic morphology should be distinguished from the pleomorphic variant. In addition, the differential diagnosis for pleomorphic MCL may include nonhematopoietic malignancies including melanoma, carcinoma, or sarcoma with pleomorphic features. Along with flow cytometry and other immunohistochemical markers, cyclin D1 or SOX-11 are very helpful markers for confirming MCL. Furthermore, FFPE tissue or cytology specimens can be used to perform fluorescence in situ hybridization for t(11;14) IgH-CCND1 gene rearrangements in difficult cases. 21 The limitations of cytology alone in the evaluation of lymphoproliferative diseases stems from the wide cytomorphologic spectrum of reactive lymphadenopathies that overlap with a variety of lymphomas. Due to difficulty in establishing an exact lymphoma subtype diagnosis, even when FNAB and CNB are combined, an excisional lymph node biopsy may be required in approximately one-quarter of cases. 3 The inability to assess lymph node architecture is another limitation of FNAB, although in cases of MCL the histologic pattern has limited or no correlation with prognosis and outcome. 5, 8 In the current study, the subtype that FNAB had the most difficulty identifying was the pleomorphic variant. This may be due to the focal nature of pleomorphic cells within a background of small to intermediate-sized cells. Two cases classified as being of the blastoid variant and 3 cases of MCL-HPI were diagnosed on FNAB but not CNB. The majority of histologic diagnoses in the current study were detected by CNB rather than excisional biopsy, and therefore, variable tissue sampling may be attributed to some cases described as having variant morphology on FNAB but not by CNB. Caution should be taken when evaluating cytomorphology on specimens with airdrying, which can artificially enlarge cells, leading to a more blastic appearance. Standardized recommendations for assessing Ki-67 are needed to help avoid overestimation of the proliferation index. FNAB has been established as a less expensive and less invasive procedure, and often is the preferred approach for the initial evaluation of disease by many institutions. FNAB with ROSE at the time of the initial assessment of a patient with lymphadenopathy is particularly useful and on-site evaluation allows for appropriate specimen triage such as sending microbial cultures in cases suspicious for infection, the collection of fresh tissue for flow cytometry in cases suspicious for lymphoproliferative disorders, and processing for cell block specimens in cases demonstrating solid tumor metastasis or for molecular testing. At the time of aspiration, requesting a CNB also can be done. In the current study, approximately 93% of cases with FNAB with flow cytometry were appropriately classified as MCL and variant morphology was accurately detected in 74% of cases. With specification of variant cytomorphology and the use of Cancer Cytopathology January 2019 cytology preparations for immunoperoxidase staining for cyclin D1, SOX-11, and Ki-67, a definitive and clinically actionable diagnosis can be achieved by cytology. FNAB is particularly useful in patients with recurrent/residual disease.
Conclusions
To our knowledge, the current study is the first to evaluate the ability of FNAB to detect the morphologic variants of MCL. FNAB with ROSE helps to ensure the triaging of appropriate tissue collection in the workup of patients with lymphoproliferative disorders. Reviewed in conjunction with immunophenotyping by flow cytometric and immunohistochemical stains, FNAB can provide a definitive and clinically actionable diagnosis of MCL with subtyping. In the hospital setting in the current study, it was not uncommon to diagnose MCL with variant morphology or a nontraditional immunophenotype. Therefore, in this era of small biopsy samples, it is optimal to obtain FNAB, flow cytometry, and CNB to guarantee an appropriate diagnosis for patient care.
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